top of page

Norbert Hittel


Background: MD, Chief Scientific Officer at Otsuka Novel Products Munich. Involved in clinical development for more than 10 years and Regulatory Approval of new TB compounds, in particular in charge of the clinical Phase 1 and EBA development and Regular Approval of delamanid in the EU.

bottom of page